EP0229026B1 - Produit sanguin thérapeutique, procédés et méthodes pour le préparer - Google Patents

Produit sanguin thérapeutique, procédés et méthodes pour le préparer Download PDF

Info

Publication number
EP0229026B1
EP0229026B1 EP87300036A EP87300036A EP0229026B1 EP 0229026 B1 EP0229026 B1 EP 0229026B1 EP 87300036 A EP87300036 A EP 87300036A EP 87300036 A EP87300036 A EP 87300036A EP 0229026 B1 EP0229026 B1 EP 0229026B1
Authority
EP
European Patent Office
Prior art keywords
factor
column
divalent metal
salt
metal ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP87300036A
Other languages
German (de)
English (en)
Other versions
EP0229026A3 (en
EP0229026A2 (fr
Inventor
Kenneth J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blood Systems Inc an Arizona not-for-profit Corp
BLOOD SYSTEMS Inc
Original Assignee
Blood Systems Inc an Arizona not-for-profit Corp
BLOOD SYSTEMS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25220193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0229026(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blood Systems Inc an Arizona not-for-profit Corp, BLOOD SYSTEMS Inc filed Critical Blood Systems Inc an Arizona not-for-profit Corp
Publication of EP0229026A2 publication Critical patent/EP0229026A2/fr
Publication of EP0229026A3 publication Critical patent/EP0229026A3/en
Application granted granted Critical
Publication of EP0229026B1 publication Critical patent/EP0229026B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to blood component therapy and more particularly to unique means and methods of purifying factor IX from prothrombin complex concentrates or other sources of factor IX including culture supernatants containing factor IX from recombinant DNA technology.
  • An improved therapeutic blood product will be prepared using the present invention.
  • Blood component therapy made possible by the development of a closed system of multiple plastic collecting bags and high speed refrigerated centrifuges, is one of the most important advances in the history of blood transfusion practices.
  • the rationale for use of specific fractions of blood is that blood contains a number of differently formed elements as well as various plasma proteins and constituents which have many functions.
  • a single donation of a unit of whole blood can provide red blood cells, platelets, plasma, and cryoprecipitated factor VIII - fibrinogen concentrate.
  • Pheresis procedures are able to supply large quantities of granulocytes, platelets, and plasma from single donors.
  • Plasma can be chemically fractionated to provide albumin or plasma protein fraction, factor VIII concentrate, factor IX complex and immune serum globulin.
  • Factor IX complex is a lyophilized pooled plasma derivative rich in Factors IV, VII, II and X. It is an alternative to plasma therapy. It supplies vitamin K-dependent clotting factors in a much smaller volume than plasma but with a significantly higher hepatitis risk.
  • Factor IX containing concentrates are a unique and highly valuable blood product which are life-saving when used to control bleeding in patients suffering with factor IX deficiency (Hemophilia "B"). These products have also been used to treat those patients afflicted with Hemophilia "A” having inhibitors although clinical verification of this application is still in progress. Factor IX containing concentrates are also used to arrest serious hemorrhages or to avert operative and post operative bleeding in patients with other congenital clotting factor deficiencies and for multiple factor deficiency induced by an overdose of warfarin-type drugs, i.e., oral anticoagulants.
  • warfarin-type drugs i.e., oral anticoagulants.
  • the present invention is directed to purifying factor IX complex and thereby permits the production of a high purity factor IX therapeutic blood product therefrom.
  • the present invention relates to the utilization of A-7 monoclonal antibody (see: Smith KJ and Ono K, "Monoclonal antibodies to Factor IX: characterization and use in immunoassays for Factor IX", Thrombosis Research 1984, 33; 211-224) to purify a crude factor IX complex irrespective of which divalent ion is present and permit the production of an improved purified therapeutic blood product thereform having enhanced effectiveness in controlling bleeding incidents arising from a deficiency of clotting factor IX.
  • the A-7 monoclonal antibody used in the method of the present invention is uniquely suited for use in affinity chromotography to purify factor IX complex by separating extraneous protein therefrom and by its unique ability to specifically bind factor IX. More particulary, the present invention is predicated upon my discovery of a novel and unique method of obtaining purified factor IX from crude factor IX complex by coupling an A-7 antibody to agarose and like matrices including polyacrylamide, cellulose, and cellulose derived membrane in a column into which a specially buffered factor IX concentrate-benzamidine solution is flowed until the factor IX enzyme is selectively extracted therefrom.
  • the purified factor IX concentrate is then recovered using buffered ethylene diamine tetraacetic acid ("EDTA”), ethyleneglycol-tris( ⁇ -amino-ethyl ether)-N,N,N',N'-tetraacetic acid (“EGTA”) or sodium citrate and is thereafter concentrated and packaged after its release from the column.
  • EDTA buffered ethylene diamine tetraacetic acid
  • EGTA ethyleneglycol-tris( ⁇ -amino-ethyl ether)-N,N,N',N'-tetraacetic acid
  • sodium citrate sodium citrate
  • a prime object of the present invention is to provide improved methodology for producing purified factor IX from crude factor IX complex, or from tissue culture supernatants where factor IX has been produced by recombinant DNA technology, and to provide an enhanced factor IX therapeutic blood product therefrom.
  • the present invention provides a process for purifying human factor IX from an impure source of factor IX comprising the steps of:
  • a monoclonal antibody is obtained from mouse ascites.
  • the A-7 producing hybridoma is injected into the peritoneal cavity of mice given intraperitoneal pristane (0.5 cc) 1-10 weeks previously using the procedure of Anson et al, supra.
  • Mice are given cyclophosphamide (20 micrograms per gram body weight) one day prior to intraperitoneal injection of the hybridoma using the technique described by Galfre and Milstein (Preparation of monoclonal antibodies: Strategies and procedures. Methods in Enzymology , Vol 73, Immunochemical Techniques, Part B, New York; Academic Press, 1981: 3-46.)
  • Ascites fluid is removed by needle and stored frozen at -20°C until purification.
  • the ascites fluid is treated with 0.1 mM PMSF (phenyl methyl sulfonyl- fluoride, Sigma Chemical Company, St. Louis, Missouri) for 20 minutes at room temperature and all debris removed by centrifugation.
  • Antibody is precipitated by addition of solid ammonium sulfate to 50 percent saturation at 4°C for 15 minutes.
  • the antibody containing precipitate is obtained after centrifugation (10,000 g for 20 minutes) and washed with 50% saturated ammonium sulfate in 0.15 M NaCl 0.05 M Tris pH 7.5. This and all further steps are performed at 4°C.
  • the final concentrate obtained after recentrifugation is dissolved in 0.01M sodium phosphate pH 7.5 and dialyzed overnight against three changes of 100 volumes of buffer.
  • the antibody concentrate is applied to a DEAE Sephadex® A50 column (Pharmacia Fine Chemicals, Piscataway, New Jersey) of the appropriate size determined by the capacity of the gel following the manufacturer's instructions.
  • the column is washed with 0.01M sodium phosphate until the absorbance at 280 nM reached a level of 0.1 or less in a 1 cm light path and then the protein is eluted using a linear gradient of 0.3M NaCl in 0.01M sodium phosphate and an equal volume of 0.01M sodium phosphate.
  • the total elution volume is six times the column volume.
  • Antibody containing fractions are detected by an ELISA system using factor IX immobilized on microtiter plates using the technique reported in "Monoclonal antibodies to factor IX: Characterization and use in immunoassays for factor IX.” Thrombosis Research , 1984:33:211-224.
  • the antibody containing fractions are pooled and concentrated using pressure filtration and a YM-30 membrane filtration cell (Amicon Corporation, Danvers, MA).
  • the preparation is further purified by Sepacryl® S-200 gel filtration in 0.2M NaCl .01M Tris-HCl pH 7.5 and antibody containing fractions are identified, pooled, and concentrated as discussed above.
  • An alternative to the ion exchange chromatography described above is to dialyze the ammonium sulfate precipitated antibody in 0.02M Tris-HCl pH 7.2 prior to application to a blue dye and diethylamino ethyl derivatized cross-linked agarose gel bed support ("DEAE-Affigel"-Blue column, BioRad Laboratories, Richmond, CA).
  • the protein is eluted using a linear gradient made up with equal volumes of 0.02M Tris-HCl and 0.02M Tris-HCl with 0.15M NaCl.
  • Antibody containing fractions are identified and concentrated as previously described.
  • the gel is equilibrated in 0.05M NaCl-0.05M Tris-HCl pH 7.5 (TBS) with 20 mM magnesium chloride.
  • TBS Tris-HCl pH 7.5
  • Factor IX containing commercial concentrates or tissue culture supernatants containing factor IX are treated with magnesium added at a final concentration of 20 mM, and benzamidine HCl 10 mM prior to application to the A-7 matrix.
  • the column used contains a 20-fold excess of antibody to factor IX to be bound by weight.
  • vitamin K-dependent coagulation factors include Proplex® (Hyland Division, Baxter Travenol, Costa Mesa, CA), Konyne® (Cutter Laboratories, Berkeley, CA), and Profilnine® (Alpha Therapeutics, City of Industry, CA).
  • the metal ion-dependent purification process can be implemented with calcium chloride and EGTA or EDTA and other divalent cations, such as manganese followed by EDTA.
  • This process is particularly suited for purifying factor IX from tissue culture supernatants containing fetal calf serum since the A-7 antibody binds to recombinant factor IX but not to bovine factor IX.
  • a monoclonal antibody is purified from tissue culture supernatants. All purification steps are at 4 degrees centigrade.
  • the A-7 antibody is purified from tissue culture supernatant by precipiation after adding ammonium sulfate to a final saturation of 50% at 4 degrees centigrade.
  • the pellet obtained from this material is resuspended in 0.02 M Tris-HCl (pH 7.2) and dialyzed prior to chromatography on DEAE-Affigel Blue (Bio-Rad Laboratories, Richmond, CA) or DEAE-Sephadex® A-50 (Pharmacia Inc., Piscataway, NJ).
  • the A-7 antibody is separated from contaminating proteins by a salt gradient from 0 to 0.4 M NaCl.
  • Antibody containing fractions are dialyzed in 0.1 M HEPES buffer pH 7.0 and concentrated using a YM-30 membrane and a pressure filtration cell (Amicon Corporation, Danvers, MA).
  • the antibody is coupled to Affigel® 10 (Bio-Rad Laboratories) at a protein content of 10 mg of antibody per one ml of gel by mixing antibody and gel on a rotator overnight.
  • CNBr activated Sepharose® 4B Pharmacia Inc.
  • activated Bio-Gel® A5M Bio-Rad Laboratories
  • CNBr-activated Sepharose® 4B and CNBr activated Bio-gel® A5M must be at pH 9 in 0.1 M sodium carbonate buffer.
  • factor IX (4800U) or factor IX from other sources is dissolved in water according to the manufacturer's directions (Cutter Laboratories, Berkeley, CA; Hyland Laboratories, Costa Mesa, CA; Alpha Therapeutics, Los Angeles, CA).
  • Benzamidine (Aldrich Chemical Co., Milwaukee, WI) is added to a final concentration of 10 mM and the concentrate is then mixed with an equal volume of 0.1 M Tris-HCl/0.1 M NaCl pH 7.5 with 20 to 40 mM magnesium chloride.
  • the concentrate thus produced is applied to a 20 ml column of agarose coupled to 200 mg of monoclonal antibody A-7, produced as described above, for 2-6 hours.
  • the column is then washed with two column volumes of 0.05 M Tris-HCl/0.05 M NaCl pH 7.5 and 6 to 10 column volumes of 1M-3M NaCl in 0.05 M Tris-HCl pH 7.5. Washing is continued until there is only minimal protein (less than 20 micrograms per ml) in column effluent as determined by absorbance at 280 nm assuming an extinction coefficient of 10 for a 1% protein solution.
  • the Factor IX is then eluted with 20 mM EDTA in 0.05 M Tris-HCl/0.05 NaCl, pH 7.5. Fractions containing protein are then concentrated using a pressure filtration cell and a YM-30 membrane (Amicon Corporation).
  • Solvent exchange can be accomplished using the pressure filtration cell prior to lyophilization or preparation for infusion.
  • the highly purified factor IX produced hereby can then be lyophilized for patient delivery using conventional technology when combined with physiologically acceptable excepients such as glucose, maltose, citrate buffered saline, HEPES and the like, including mixtures thereof.
  • physiologically acceptable excepients such as glucose, maltose, citrate buffered saline, HEPES and the like, including mixtures thereof.
  • A-7 monoclonal antibody was prepared by purifying ascites obtained from Balb/c mice injected with a hybridoma in the peritoneal cavity into which 0.5cc pristane had been injected from 1 to 10 weeks previously and cyclophosphamide (20 micrograms per gram body weight) injected 24 hours earlier.
  • the ascites fluid was removed by needle and stored at -20°C until purification.
  • the ascites fluid was treated with 0.1 mM pheny methyl sulfonyl-fluoride (PMSF) for 20 minutes at room temperature and all debris was then removed therefrom by centrifugation.
  • the antibody was then precipitated by the addition of solid ammonium sulfate to a 50 percent saturation at 4°C for 15 minutes.
  • the antibody containing precipitate was obtained after centrifugation at 10,000 g for 20 minutes and thereafter washed with 50 percent saturated ammonium sulfate in 0.15 M NaCl, 0.05 M Tris, pH 7.5 at 4°C.
  • the final concentrate obtained after recentrifugation was dissolved in 0.01M sodium phosphate (pH 7.5) and dialyzed overnight against three changes of 100 volumes of buffer.
  • This antibody concentrate was then applied to a DEAE Sephadex® A50 column and washed with 0.1 sodium phosphate until the absorbance at 280 nm reached a level of 0.1 or less in a 1 cm light path.
  • the protein was then eluted at 4°C using a linear gradient of 0.3M NaCl in 0.01M sodium phosphate and an equal volume of 0.01M sodium phosphate. The total elution volume was six times the column volume.
  • the antibody containing fractions were detected by the ELISA system and thereafter pooled and concentrated using pressure filtration and a YM-30 membrane and filtration cell (Amicon). The pool was stored at 4°C for future use.
  • factor IX was isolated from plasma obtained from patients undergoing therapeutic plasmapheresis. All purification steps were performed at four degrees centigrade. 294 grams of trisodium citrate dihydrate were added to 100 liters of plasma and the mixture was stirred until the sodium citrate had dissolved. Four liters of 1 M BaCl2 were then added and the preparation was stirred for 15 minutes prior to centrifugation at 4000 g for 10 minutes. The supernatant plasma was discarded.
  • the barium citrate precipitate obtained was then twice suspended in 0.15 M NaCl with 10 mM BaCl2 and 1 mM Benzamidine and separated from the washing solution by centrifugation at 4000 g for 10 minutes.
  • the barium citrate precipitate was then suspended on 1 M Na2SO4 with 5 mM Benzamidine and after stirring for 15 minutes, the sodium sulfate precipitate obtained was then separated from supernatant plasma by centrifugation at 4000 g for 15 minutes.
  • the supernatant was then dialyzed against 0.025 sodium citrate pH 6.0 with 1 mM Benzamidine overnight and then applied to 1000 ml column of DEAE-Sepharose® (Pharmacia Fine Chemicals, Piscataway, NJ).
  • All buffers in the purification procedure contained 1 mM Benzamidine.
  • the factor IX containing fractions were obtained by a linear salt gradient where starting and finishing buffers were 3 liters of 0.025 M sodium citrate pH 6.0 and 3 liters of 0.025 M sodium citrate pH 6.0 with 0.7 M NaCl.
  • the factor IX containing fractions were precipitated by adding solid ammonium sulfate to 65% saturation and then dialyzed overnight in 0.025 M sodium citrate pH 7.4 and applied to a 1000 ml column of Dextran-Sulfate agarose prepared by coupling Dextran-Sulfate (Pharmacia Fine Chemicals, Piscataway, NJ) to cyanogen bromide activated agarose (200 mg Dextran Sulfate per ml of gel).
  • Factor IX containing fractions were obtained by a linear salt gradient with 3 liters of 0.025 M sodium citrate and 3 liters of 0.025 M sodium citrate with 1.0 M NaCl.
  • This partially purified preparation of factor IX was then dialyzed in TBS (0.1 M NaCl and 0.05 M Tris-HCl pH 7.5 with 1 mM Benzamidine) in preparation for passage over the A-7 antibody column.
  • the washed partially purified factor IX was then applied to a 14 ml column of Affigel®-10 having 75 mg of the A-7 antibody (prepared according to EXAMPLE I) bound thereto which was first extensively washed with TBS (0.1 M NaCl, 0.05 Tris HCl, pH 7.5).
  • the application buffer was TBS with 0.1% Tween®-20 (Sigma Chemical Co., St. Louis, MO), 5 mM MgCl2 and 1 mM Benzamidine-HCl.
  • the column was washed with 3M NaCl in 0.05M Tris-HCl pH 7.5 with 5 mM MgCl2 and 1 mM Benzamidine HCl and factor IX (7.7 mg) was eluted with 20 mM EDTA.
  • Protein purity of factor IX was verified by immunologic testing using goat antisera to factor IX and immunoassays for factor IX using monoclonal antibodies. Clotting activity was verified by the ability of this protein to correct the clotting time of plasma from a patient known to be deficient in factor IX. The eluted protein appeared to be over 95% factor IX as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Clotting activity in units/per milligram was 160, 187 and 313 on three different specimens.
  • Example II A variation of the method of Example II was conducted using the same A-7 antibody Affigel® 10 column, but the source of factor IX was an eluate from barium citrate.
  • the source of factor IX was an eluate from barium citrate.
  • three liters of plasma were obtained from a single individual undergoing therapeutic plasmapheresis.
  • Benzamidine was added to plasma at a final concentration of 1 mM.
  • a barium citrate precipitate was obtained by adding 17.48 grams of BaCl2 2H2O per liter and stirring for 1 hour at 4 degrees centigrade. The precipitate was recovered by cetrifugation at 4000 g for 15 minutes and supernatant plasma was discarded.
  • a third source of factor IX was tested using the same A-7 Affigel® 10 column over a period of 30 days, a total of 25.1 mg of factor IX was purified using Konyne (Cutter Laboratories, Berkeley, CA) Lot NC9127 as the starting material. Prior to application to the column, the commercial concentrate of factor IX was made to 10 mM MgCl2 and 10 mM Benzamidine. Specific activity of the purified factor IX was 313 and 386 units per mg.
  • a larger column of the A-7 antibody was made by coupling 194 mg of antibody A-7 to 55 ml of Affigel® 10 and 41.3 mg of factor IX was purified using the same lot of Cutter concentrate as in Example IV.
  • the application buffer (TBS) used consisted of 10 mM MgCl2 and 10 mM Benzamidine.
  • Factor IX partially purified as described in Example II, was passed over the column and produced 20.2 mg of purified factor IX.
  • a DEAE-Sepharose® extract of plasma was used as the source of factor IX.
  • the plasma was obtained from individuals (3 to 12 liters) and treated with 10 mM Benzamidine prior to addition of 80 ml/liter of DEAE-Sepharose® which had been equilibrated in 0.025 M sodium citrate pH 6.5. After stirring for one hour at room temperature, the Sepharose® was collected by filtration and washed with 6 volumes of 0.025 M sodium citrate pH 6.5. The factor IX containing fractions were then eluted by a linear gradient of 0.025 M sodium citrate pH 6.5 to 0.5 M NaCl in 0.025 M sodium citrate pH 6.5 both with 1 mM Benzamidine.
  • each buffer was three times the column volume. Protein fractions were then pooled and dialyzed in TBS with 1 mM Benzamidine prior to application to the A-7 antibody column. Magnesium concentration was 20 mM in this case. 32 mg of factor IX were prepared.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (11)

  1. Procédé pour purifier le facteur IX humain à partir d'une source impure du facteur IX, comprenant les étapes consistant à :
    a) procurer une colonne d'anticorps monoclonaux A-7 couplés à un support matriciel;
    b) appliquer, sur la colonne, une solution d'application comprenant la source impure du facteur IX et un sel d'ion métallique divalent;
    c) éluer le facteur IX de la colonne avec une solution comprenant un agent de chélation; et
    d) récupérer le facteur IX élué.
  2. Procédé selon la revendication 1, dans lequel lesdits anticorps monoclonaux A-7 sont caractérisés comme étant réactifs avec le facteur IX humain en présence d'ion métallique divalent, comme étant non réactifs avec le facteur IX humain en l'absence d'ion métallique divalent et comme étant non réactifs avec le facteur IX bovin.
  3. Procédé selon la revendication 1 ou 2, dans lequel le sel d'ion métallique divalent de la solution d'application est un sel de calcium, de cuivre, de magnésium, de manganèse ou de zinc.
  4. Procédé selon la revendication 1, 2 ou 3, dans lequel le sel d'ion métallique divalent de la solution d'application est un sel de cadmium, de strontium ou de baryum.
  5. Procédé selon l'une quelconque des revendications précédentes, dans lequel la solution d'application englobe, en outre, la benzamidine.
  6. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'agent de chélation est le EDTA, le EGTA ou un sel de citrate.
  7. Procédé selon l'une quelconque des revendications précédentes, qui englobe, en outre, l'étape e) consistant à séparer le facteur IX de l'agent de chélation pour ions métalliques divalents.
  8. Procédé selon l'une quelconque des revendications précédentes, qui englobe, en outre, après avoir appliqué la solution d'application, une étape de lavage de la colonne avec une solution de lavage comprenant un sel d'ion métallique divalent.
  9. Procédé selon la revendication 8, dans lequel le sel d'ion métallique divalent de la solution de lavage est un sel de calcium, de cuivre, de magnésium, de manganèse ou de zinc.
  10. Procédé selon la revendication 8, dans lequel le sel d'ion métallique divalent de la solution de lavage est un sel de cadmium, de strontium ou de baryum.
  11. Procédé selon l'une quelconque des revendications précédentes, dans lequel le support matriciel est le polyacrylamide, la cellulose ou l'agarose.
EP87300036A 1986-01-06 1987-01-06 Produit sanguin thérapeutique, procédés et méthodes pour le préparer Revoked EP0229026B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81629186A 1986-01-06 1986-01-06
US816291 1986-01-06

Publications (3)

Publication Number Publication Date
EP0229026A2 EP0229026A2 (fr) 1987-07-15
EP0229026A3 EP0229026A3 (en) 1988-12-21
EP0229026B1 true EP0229026B1 (fr) 1995-11-22

Family

ID=25220193

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87300036A Revoked EP0229026B1 (fr) 1986-01-06 1987-01-06 Produit sanguin thérapeutique, procédés et méthodes pour le préparer

Country Status (4)

Country Link
EP (1) EP0229026B1 (fr)
AT (1) ATE130620T1 (fr)
CA (1) CA1288711C (fr)
DE (1) DE3751605D1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034222A (en) * 1994-10-04 2000-03-07 Bio-Products & Bio-Engineering A.G. Method for the separation of recombinant pro-factor IX from recombinant factor IX

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631830B1 (fr) * 1988-05-25 1991-06-21 Lille Transfusion Sanguine Concentre de facteur ix de haute purete, sa preparation et son utilisation en therapeutique
DE3877529T2 (de) * 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
CA2143125C (fr) * 1992-08-27 2008-09-23 Koenraad Mertens Anticorps specifiques pour une proteine hemostatique, leur utilisation pour l'isolement de la proteine intacte, les compositions hemostatiques depourvues de produits de degradation proeolytique de la proteine
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
US20090111751A1 (en) * 2006-02-24 2009-04-30 Novo Nordisk Health Care Ag Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118256B1 (fr) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbant et procédé de récupération de protéines dépendantes de la vitamine-K utilisant cet adsorbant
JPS61500226A (ja) * 1983-10-28 1986-02-06 ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド コンホメ−ション特異性抗体を用いる血液凝固タンパク質の精製および単離法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 100, no. 15, 09 April 1984, Columbus, OH (US); K.J. SMITH et al., p. 269, no. 117303a/ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034222A (en) * 1994-10-04 2000-03-07 Bio-Products & Bio-Engineering A.G. Method for the separation of recombinant pro-factor IX from recombinant factor IX
AT406865B (de) * 1994-10-04 2000-10-25 Bio Prod & Bio Eng Ag Verfahren zur trennung und gewinnung von rekombinantem pro-faktor ix von rekombinantem faktor ix

Also Published As

Publication number Publication date
CA1288711C (fr) 1991-09-10
DE3751605D1 (de) 1996-01-04
EP0229026A3 (en) 1988-12-21
EP0229026A2 (fr) 1987-07-15
ATE130620T1 (de) 1995-12-15

Similar Documents

Publication Publication Date Title
US5457181A (en) Preparation of a high-purity human factor IX concentrate and other plasmatic proteins and their therapeutic use
US5219995A (en) Plasma fraction purification
FI106721B (fi) Menetelmä ihmisen standardisoidun, korkean puhtauden omaavan von Willebrand -tekijän konsentraatin valmistamiseksi
US5580962A (en) Parenterally administrable drug having thrombolytic activity and containing protein C
US5679776A (en) Process for preparing a concentrate of blood coagulation factor VIII-von willebrand factor complex from total plasma
EP0411810B1 (fr) Purification du complexe du facteur VIII en utilisant la chromatographie d'affinité sur l'héparine
US4786726A (en) Factor IX therapeutic blood product, means and methods of preparing same
EP1820509B1 (fr) Préparation thérapeutique de FVlla à pureté très élevée, et procédé pour l'obtenir
Kondo et al. Evidence that plasma lipoproteins inhibit the factor VIIa-tissue factor complex by a different mechanism that extrinsic pathway inhibitor
EP0162078B1 (fr) Procede d'isolation d'une proteine d'un melange la contenant et un anticorps specifique de conformation
US3943245A (en) Purification of plasminogen
JPH0424360B2 (fr)
US6063909A (en) Preparation of factor IX
US4510084A (en) Method of producing an antithrombin III-heparin concentrate or antithrombin III-heparinoid concentrate
EP0229026B1 (fr) Produit sanguin thérapeutique, procédés et méthodes pour le préparer
AU9244998A (en) Pharmaceutical substance containing various vitamin k-dependent factors
JP2824430B2 (ja) 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
Owens et al. Net biosynthesis of antithrombin III by the isolated rat liver perfused for 12–24 hours compared with rat fibrinogen and α-2 (acute-phase) globulin, antithrombin III is not an acute phase protein
US4977246A (en) High recovery process for antihemophilic factor
EP0253331B1 (fr) Substance se liant à la thrombine et son procédé de préparation
Theodorsson et al. A technique for specific removal of factor IX alloantibodies from human plasma: partial characterization of the alloantibodies
Regnault et al. Monoclonal antibodies against human plasma protein C and their uses for immunoaffinity chromatography
US5204256A (en) Process for the purification of plasminogen activator inhibitor 2 (pai-2)
de Lille llllll" 111 ill Ilill ll| l| lllll lllll|||| l lilil lllll| l|||" II" III lllll| ll|
JPH0329390B2 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19890614

17Q First examination report despatched

Effective date: 19920421

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 19951122

Ref country code: BE

Effective date: 19951122

Ref country code: FR

Effective date: 19951122

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19951122

REF Corresponds to:

Ref document number: 130620

Country of ref document: AT

Date of ref document: 19951215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3751605

Country of ref document: DE

Date of ref document: 19960104

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI & CO. PATENTANWAELTE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960223

Ref country code: DE

Effective date: 19960223

EN Fr: translation not filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: CANTEON PHARMA GMBH

Effective date: 19960820

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20000112

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20000126

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20000127

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010106

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010131

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20010106

R26 Opposition filed (corrected)

Opponent name: AVENTIS BEHRING GMBH

Effective date: 19960820

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

RDAH Patent revoked

Free format text: ORIGINAL CODE: EPIDOS REVO

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 20020719